Atypical IgM multiple myeloma with deletion of c-MAF

被引:0
|
作者
Juarez Salcedo, L. M. [1 ]
Lopez Rubio, M. [1 ]
Gil Fernandez, J. J. [1 ]
Garcia-Suarez, J. [1 ]
Magro, E. [1 ]
Arranz, E. [2 ]
Gutierrez Jomarron, I. [1 ]
Marcellini Antonio, S. [1 ]
Blasco, A. [3 ]
Burgaleta, C. [1 ,4 ]
机构
[1] Hosp Univ Principe Asturias, Div Hematol, Alcala De Henares, Spain
[2] Hosp Univ Princesa, Cytogenet Div, Alcala De Henares, Spain
[3] Hosp Univ Principe Asturias, Div Anat Pathol, Madrid, Spain
[4] Univ Alcala Henares, Dept Med, Madrid, Spain
关键词
Multiple myeloma; Waldenstrom's macroglobulinemia; C-MAF; T(11/14)(Q13; Q32); TRANSLOCATION; SPECTRUM; ENTITY; RARE;
D O I
10.1111/ijlh.12385
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IgM multiple myeloma (MM) is a rare subtype of myeloma that shares clinical and pathological features with Waldenstrom's macroglobulinaemia. These are two separate entities that differ both in therapy and prognosis. We report a 57-year-old male, who presented with anaemia, hypercalcaemia, acute renal failure and several vertebral fractures that clinically suggested a multiple myeloma. Further investigations revealed a serum monoclonal component of IgM lambda type and a bone marrow infiltrated by small, lymphoplasmocytic cells. IgM MM was finally diagnosed by means of both inmunophenotypic and immunohistochemistry techniques, stressing the importance of inmunophenotypic evaluation when clinical and morphological features are discordant. Fluorescence in situ hybridization (FISH) studies disclosed a particular combination of deletion 13q14, t(11;14) and monoallelic deletion C-MAF without t(14; 16). The clinical evolution after a Bortezomib-containing polychemotherapy and autologous stem cell transplantation (ASCT) conditioned with busulphan and melphalan is also presented. This very uncommon case highlights the impact of immunophenotyping on the differential diagnosis between IgM MM and WM, to choose the best treatment and establish an appropriate outcome.
引用
收藏
页码:686 / 689
页数:4
相关论文
共 50 条
  • [1] Targeting the oncogenic transcription factor c-Maf for the treatment of multiple myeloma
    Jiang, Qiuyun
    Mao, Hongwu
    He, Guisong
    Mao, Xinliang
    CANCER LETTERS, 2022, 543
  • [2] c-maf oncogene dysregulation in multiple myeloma: Frequency and biological relevance
    Rasmussen, T
    Knudsen, LM
    Dahl, IMS
    Johnsen, HE
    LEUKEMIA & LYMPHOMA, 2003, 44 (10) : 1761 - 1766
  • [3] Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
    Wei, GuoQing
    Wang, LiJun
    Yang, HanJin
    Han, XiaoYan
    Zheng, GaoFeng
    Zheng, WeiYan
    Sun, Jie
    Shi, JiMin
    Wu, WenJun
    Zhao, Yi
    He, DongHua
    Wang, Bo
    Cai, Zhen
    He, JingSong
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2017, 6
  • [4] Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
    GuoQing Wei
    LiJun Wang
    HanJin Yang
    XiaoYan Han
    GaoFeng Zheng
    WeiYan Zheng
    Jie Sun
    JiMin Shi
    WenJun Wu
    Yi Zhao
    DongHua He
    Bo Wang
    Zhen Cai
    JingSong He
    Experimental Hematology & Oncology, 6
  • [5] Ubiquitination of the transcription factor c-MAF is mediated by multiple lysine residues
    Chen, Guodong
    Xu, Xin
    Tong, Jiefei
    Han, Kunkun
    Zhang, Zubin
    Tang, Juan
    Li, Siyue
    Yang, Chuanqi
    Li, Jie
    Cao, Biyin
    Zhou, Haixia
    Wu, Depei
    Moran, Michael F.
    Mao, Xinliang
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2014, 57 : 157 - 166
  • [6] Identification of small compounds that inhibit multiple myeloma proliferation by targeting c-Maf transcriptional activity
    Asano, Kenichi
    Kikuchi, Kenta
    Takehara, Miki
    Ogasawara, Manami
    Yoshioka, Yuki
    Ohnishi, Kie
    Iwata, Ayaka
    Shimizu, Shigeomi
    Tanaka, Masato
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 684
  • [7] Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma
    Wang, Ying
    Li, Qinlu
    Xing, Shugang
    Zhang, Heng
    Li, Dengju
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (09) : E545 - E550
  • [8] Developmental contribution of c-maf in the kidney: distribution and developmental study of c-maf mRNA in normal mice kidney and histological study of c-maf knockout mice kidney and liver
    Imaki, J
    Tsuchiya, K
    Mishima, T
    Onodera, H
    Kim, JI
    Yoshida, K
    Ikeda, H
    Sakai, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 320 (04) : 1323 - 1327
  • [9] The role of interleukin 22 in multiple sclerosis and its association with c-Maf and AHR
    Zarobkiewicz, Michal Konrad
    Kowalska, Wioleta
    Slawinski, Miroslaw
    Rolinski, Jacek
    Bojarska-Junak, Agnieszka
    BIOMEDICAL PAPERS-OLOMOUC, 2019, 163 (03): : 200 - 206
  • [10] Inhibition of the Otub1/c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis
    Sun, Tong
    Xu, Yujia
    Xu, Zhuan
    Cao, Biyin
    Zhang, Zubin
    Wang, Qi
    Kong, Yan
    Mao, Xinliang
    CELL COMMUNICATION AND SIGNALING, 2021, 19 (01)